Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
31 Jul 2025	Piramal Pharma	Consensus Share Price Target	201.37	265.00	-	31.60	buy	pdf Detailed Estimates
15 May 2025	Piramal Pharma	Motilal Oswal Target	201.37	250.00	208.61 (-3.47%)	24.15	Buy	pdf post cache	Broker Report Operationally, in-line 4Q; FY25 ends on a strong note Motilal Oswal Piramal Pharma (PIRPHARM) delivered in-line sales/EBITDA in 4QFY25. However, its earnings were below our estimate due to impairment of certain intangible assets during the quarter. pdf Copy Link Share on Share on Share on Share on Alert
30 Jan 2025	Piramal Pharma	Edelweiss Target	201.37	283.00	231.25 (-12.92%)	40.54	Buy	pdf post cache	Broker Report Piramal Pharma \| Q3FY25 Result Update Edelweiss CDMO business to drive growth pdf Copy Link Share on Share on Share on Share on Alert
24 Oct 2024	Piramal Pharma	Motilal Oswal Target	201.37	310.00	255.84 (-21.29%)	53.95	Buy	pdf post cache	Broker Report Operating performance above est.; FY25 guidance intact Motilal Oswal Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance in 2QFY25 fueled by superior traction in the CDMO segment (59% of sales). Following earnings deterioration in FY23/FY24, PIRPHARM is exhibiting healthy recovery in 1HFY25. pdf Copy Link Share on Share on Share on Share on Alert
25 Sep 2024	Piramal Pharma	ICICI Direct Target	201.37	280.00	226.31 (-11.02%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
25 Sep 2024	Piramal Pharma	Motilal Oswal Target	201.37	260.00	226.31 (-11.02%)	Target met	Buy	pdf post cache	Broker Report Geared to drive robust operating leverage across segments Motilal Oswal PIRPHARM is well-positioned to offer differentiated services at the product development and commercial manufacturing stage in the CDMO segment. pdf Copy Link Share on Share on Share on Share on Alert
12 Aug 2024	Piramal Pharma	ICICI Direct Target	201.37	230.00	185.84 (8.36%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
28 Jul 2024	Piramal Pharma	ICICI Securities Limited Target	201.37	200.00	166.51 (20.94%)	Target met	Buy	pdf post cache	Broker Report Strong orderbook, cost efficiencies boosting a turnaround ICICI Securities Limited Piramal Pharma’s Q1FY25 result was driven by better traction in innovative CDMO portfolio (50% of CDMO sales). Q1 is a seasonally weak quarter due to which its margins (10.5% in Q1FY25 vs 20.8% in Q4FY24) are volatile. pdf Copy Link Share on Share on Share on Share on Alert
22 Jul 2024	Piramal Pharma	ICICI Direct	201.37	210.00	151.42 (32.99%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
04 Jun 2024	Piramal Pharma	Ventura	201.37	248.00	144.80 (39.07%)	Target met	Buy	pdf post cache	Broker Report PIRAMAL PHARMA LTD. Ventura Innovating healthcare through integrated solutions pdf Copy Link Share on Share on Share on Share on Alert
20 May 2024	Piramal Pharma	Hem Securities	201.37	176.00	149.50 (34.70%)	Target met	Buy	pdf post cache	Broker Report PIRAMAL PHARMA LTD Hem Securities pdf Copy Link Share on Share on Share on Share on Alert
14 May 2024	Piramal Pharma	Edelweiss Target	201.37	209.00	148.90 (35.24%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma \| Q4FY24 Result Update Edelweiss CDMO business to drive growth pdf Copy Link Share on Share on Share on Share on Alert
13 May 2024	Piramal Pharma	ICICI Securities Limited	201.37	190.00	154.20 (30.59%)	Target met	Buy	pdf post cache	Broker Report Solid Q4 result; grim near-term outlook ICICI Securities Limited Piramal Pharma had a strong Q4FY24 with better-than-expected performance on all fronts. Better traction in CDMO business in FY24 drove a turnaround in operations with margins expanding 400bps YoY to ~14.6% (21.8% in Q4FY24). pdf Copy Link Share on Share on Share on Share on Alert
13 May 2024	Piramal Pharma	Motilal Oswal Target	201.37	190.00	154.20 (30.59%)	Target met	Buy	pdf post cache	Broker Report CDMO segment drives earnings Motilal Oswal Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance for the quarter. Compared to adj. loss of INR800m in FY23, PIRPHARM’s effort has led to adj. PAT of INR560m for FY24. pdf Copy Link Share on Share on Share on Share on Alert
04 Feb 2024	Piramal Pharma	Edelweiss Target	201.37	150.00	137.65 (46.29%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma \| Q3FY24 Result Update Edelweiss CDMO business to drive growth pdf Copy Link Share on Share on Share on Share on Alert
31 Oct 2023	Piramal Pharma	Edelweiss	201.37	130.00	104.50 (92.70%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma Ltd \| Q2FY24 Result Update Edelweiss Margin expansion instils confidence pdf Copy Link Share on Share on Share on Share on Alert
30 Oct 2023	Piramal Pharma	Motilal Oswal	201.37	115.00	95.45 (110.97%)	Target met	Buy	pdf post cache	Broker Report Healthy recovery in operational performance Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
05 Aug 2023	Piramal Pharma	Edelweiss	201.37	130.00	103.20 (95.13%)	Target met	Buy	pdf post cache	Broker Report Piramal Pharma \| Q1FY24 Result Update Edelweiss Margin expansion instils confidence pdf Copy Link Share on Share on Share on Share on Alert
11 Jul 2023	Piramal Pharma	Edelweiss	201.37	130.00	91.80 (119.36%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Piramal Pharma \| Long Term Recommendation Edelweiss Growth to recover on subsiding macro headwinds pdf Copy Link Share on Share on Share on Share on Alert
14 Nov 2022	Piramal Pharma	ICICI Securities Limited	201.37	200.00	139.50 (44.35%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Expect stronger H2 driven by CDMO ICICI Securities Limited Piramal Pharma’s (PPL) Q2FY23 performance was driven by growth across its business segments. Revenue grew 9.0% YoY (+16% QoQ) to Rs17.2bn. pdf Copy Link Share on Share on Share on Share on Alert
10 Nov 2022	Piramal Pharma	Motilal Oswal	201.37	185.00	142.95 (40.87%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Work-in-progress to address challenges in the CDMO segment Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert

34.60% Fall from 52W High

Piramal Pharma Ltd. share price target

Piramal Pharma Ltd. has an average share price target of 253.25. The consensus estimate represents an upside of 25.76% from the last price of 201.37. View 7 reports from 4 analysts offering long-term price targets for Piramal Pharma Ltd..

Operationally, in-line 4Q; FY25 ends on a strong note

Piramal Pharma | Q3FY25 Result Update

Operating performance above est.; FY25 guidance intact

Piramal Pharma

Geared to drive robust operating leverage across segments

Piramal Pharma

Strong orderbook, cost efficiencies boosting a turnaround

Piramal Pharma

PIRAMAL PHARMA LTD.

PIRAMAL PHARMA LTD

Piramal Pharma | Q4FY24 Result Update

Solid Q4 result; grim near-term outlook

CDMO segment drives earnings

Piramal Pharma | Q3FY24 Result Update

Piramal Pharma Ltd | Q2FY24 Result Update

Healthy recovery in operational performance

Piramal Pharma | Q1FY24 Result Update

Piramal Pharma | Long Term Recommendation

Expect stronger H2 driven by CDMO

Work-in-progress to address challenges in the CDMO segment

Advisor Screeners